A Big Mac Attack to Fight Cancer

Robert Towarnicki, CEO of SIRPant Immunotherapeutics, about the company’s immunotherapies, the advantages they offer over other approaches, and why the approach can be applied to other diseases involving immune dysfunction beyond cancer.